With recession concerns rising due to high energy prices and consumer budget tightening, investors should consider adding resilient stocks from consumer staples and healthcare sectors to their portfolios. Four dividend-paying companies recommended for recession-resistant income are Coca-Cola, Procter & Gamble, Johnson & Johnson, and Medtronic, all of which have strong track records of maintaining dividends through economic downturns.

JenaValve Technology announced the appointment of Edward Sarnowski as Chief Technology Officer to lead R&D and drive innovation following FDA approval of its Trilogy Transcatheter Heart Valve System for severe aortic regurgitation. Sarnowski brings over 20 years of medical device R&D leadership experience from Medtronic and St. Jude Medical, with expertise in structural heart and transcatheter valve technologies.

Multiple major M&A transactions and bankruptcies dominated the deal landscape. NextEra Energy agreed to acquire Dominion Energy for $66.8 billion in an all-stock deal. Shein acquired Everlane for $100 million, while Authentic Brands Group bought Lee from Kontoor Brands. IMAX is exploring a potential sale. West Marine, Del Monte Foods, Warrior Technologies, and Bitcoin Depot filed for Chapter 11 bankruptcy. Other notable deals include Medtronic's acquisition of SPR Therapeutics for $650 million and KKR's sale of CIRCOR Aerospace to Parker Hannifin for $2.55 billion.

The article highlights two healthcare stocks with high dividend yields that are expected to raise payouts: AbbVie, a pharmaceutical company with 12 blockbuster drugs and Dividend King status, and Medtronic, the largest medical device company with 48 consecutive dividend raises and strong free cash flow generation.

Medtronic is presented as an attractive investment opportunity for dividend, value, and growth investors. The stock has declined 40% from its 2021 peak, offering attractive valuations with a 3.7% dividend yield and 48 consecutive annual dividend increases. The company is ramping up its Hugo surgical robot to compete in the growing surgical robotics market, with potential for significant upside if the market recognizes its growth prospects.

The global colorectal cancer diagnostics and therapeutics market is projected to grow from USD 35 billion in 2025 to USD 73 billion by 2034 at a CAGR of ~9%. Growth is driven by rising colorectal cancer prevalence, increased screening awareness, advancements in non-invasive diagnostics (liquid biopsy, stool-based DNA tests), and emerging targeted therapies and immunotherapies. North America leads with 41% market share, while Asia-Pacific is the fastest-growing region.

CNBC's Jim Cramer warns that while the current market is compared to the 1999 dot-com bubble, today's market is actually more brutal in punishing disappointing stocks. The market is heavily concentrated in AI and data center stocks while aggressively selling healthcare and medical technology companies that miss earnings expectations. Cramer defends AI investments as producing real business results, citing strong earnings from major tech companies.

The article recommends three dividend-paying stocks for long-term investors: United Parcel Service (UPS), Hormel Foods (HRL), and Medtronic (MDT). Despite being deeply unloved and trading significantly below their 2022 highs, all three companies are undergoing business transformations with early signs of success. Each offers attractive dividend yields (6.5%, 5.6%, and 3.6% respectively) and operates in essential industries, making them suitable for holding through market uncertainty.

Medtronic, a medical device company down 40% from its 2021 peak, is attracting investor interest due to its 3.6% dividend yield and upcoming business improvements. The company is spinning off its diabetes division, launching its Hugo surgical robot to compete with Intuitive Surgical's da Vinci, and pursuing strategic acquisitions. With 48 consecutive years of dividend increases and approaching Dividend King status, analysts suggest the stock could recover as business trends improve.

The article recommends three high-yield healthcare stocks for retirees seeking income: Pfizer (6.5% yield) despite patent expirations, Medtronic (3.6% yield) with a 48-year dividend increase streak, and Omega Healthcare (5.8% yield), a senior housing REIT positioned to benefit from an aging population.

While Intuitive Surgical dominates surgical robotics with a powerful business model, its lofty 55x P/E ratio and recent 20% drawdown make it expensive. Medtronic, trading at 22x P/E with a 3.6% dividend yield and 48 consecutive annual dividend increases, presents a more attractive buy-and-hold opportunity as it launches its Hugo surgical robot with significant growth potential.

Becton Dickinson (BDX) trades at a 13x forward P/E multiple, representing a significant discount to medtech peers despite strong fundamentals including 60% U.S. infusion pump market share, 90%+ recurring revenue, and record 25% adjusted operating margins. The post-spin-off transition year narrative masks an emerging pure-play MedTech company with billion-dollar growth platforms in GLP-1 drug delivery and connected care, supported by $4 billion in fresh capital deployment and ongoing margin expansion targeting 26%+ territory.